RxDoctor Payments Data

Peter Juergensen, PA

Physician Assistant · New Haven, CTNPI 1982699799

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $5,850 of the $9,112 with a category attached, or 64.2%. Vifor Pharma, Inc. accounts for 65.1% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2021 at $6,091 and has fallen 85.8% since, to $864 in 2025. Among physician assistant clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,112in general payments, 2019–2025

Across 134 payments — averaging $68.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$6K
  • Amgen$1K
  • Travere Therapeutics, Inc.$300
  • Akebia Therapeutics Inc$263
  • Fresenius USA Marketing, Inc.$198
  • Novo Nordisk$177
  • plus $1K from 16 others

What the payments were for

  • Speaking & faculty fees$5,85064%
  • Travel & lodging$90%
  • Food & beverage$3,22635%
  • Education$270%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,112 in reported general payments places this provider in the 95th percentile of 1,795 physician assistant providers in Connecticut.

See all physician assistant providers in Connecticut

Medicare billing

Part B allowed, 2024
$46,329
Medicare patients
48
Services billed
12,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol16$22,193
LokelmaSodium Zirconium Cyclosilicate26$19,134
Sevelamer Carbonate37$3,758
Potassium Citrate ErPotassium Citrate11$2,297
Losartan Potassium31$454
Amlodipine Besylate35$250
Allopurinol26$246
Valsartan13$210
Metoprolol Succinate16$171
Carvedilol25$170
Furosemide19$149
Clonidine Hcl15$70
Atorvastatin Calcium15$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$155$41,32742 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,795 physician assistant providers in Connecticut.

Other physician assistant in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →